• 👋Hello, please SIGN-UP FOR A FREE account and become a member of our community!
    You will then be able to start threads, post comments and send messages to other members. Thanks!
  • 💪IronMag Labs® 30% Off Easter Sale👉www.ironmaglabs.com Coupon code: EASTER30🐰

PuritySourceLabs.ru MK2866 12 week treatment with 3 mg ostarine per day (Unique Study)

Vision

Team supervisor P.S.L.
Staff member
Super Moderator
Joined
Aug 20, 2013
Messages
26,894
Reaction score
17,336
Points
113
Get Shredded!
Twelve weeks of treatment with 3 mg ostarine per day (Study)
mzApZds.png

The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function
in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.

Dalton JT1, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS.
Author information

1GTx, Inc., 175 Toyota Plaza, Memphis, TN 38103 USA.

Abstract

BACKGROUND:
Cachexia, also known as muscle wasting, is a complex metabolic condition characterized by loss of skeletal muscle and a decline in physical function.
Muscle wasting is associated with cancer, sarcopenia, chronic obstructive pulmonary disease, end-stage renal disease,
and other chronic conditions and results in significant morbidity and mortality. GTx-024 (enobosarm) is a nonsteroidal selective androgen receptor modulator (SARM)
that has tissue-selective anabolic effects in muscle and bone, while sparing other androgenic tissue related to hair growth in women and prostate effects in men.
GTx-024 has demonstrated promising pharmacologic effects in preclinical studies and favorable safety and pharmacokinetic profiles in phase I investigation.

METHODS:

A 12-week double-blind, placebo-controlled phase II clinical trial was conducted to evaluate GTx-024 in 120 healthy elderly men (>60 years of age) and postmenopausal women.
The primary endpoint was total lean body mass assessed by dual energy X-ray absorptiometry,
and secondary endpoints included physical function, body weight, insulin resistance, and safety.

RESULTS:

GTx-024 treatment resulted in dose-dependent increases in total lean body mass that were statistically significant (P < 0.001, 3 mg vs. placebo) and clinically meaningful.
There were also significant improvements in physical function (P = 0.013, 3 mg vs. placebo) and insulin resistance (P = 0.013, 3 mg vs. placebo).
The incidence of adverse events was similar between treatment groups.

CONCLUSION:

GTx-024 showed a dose-dependent improvement in total lean body mass and physical function and was well tolerated. GTx-024 may be useful in the prevention
and/or treatment of muscle wasting associated with cancer and other chronic diseases.

___________________________

Twelve weeks of treatment with 3 mg ostarine per day
The successors of the anabolic steroids are called SARMs, and their development is well advanced. The spiritual father of the SARMs, James Dalton,
recently published a study in which he tried out the SARM ostarine on 120 healthy men and women.
The new drug was not completely without side effects, but it worked.

SARMs fit in the androgen receptor, but do not have a steroid structure. The enzymes that turn anabolic steroids into compounds with all kinds
of unwanted effects can therefore do nothing at all with SARMs.
That means they have fewer side effects. Hope scientists.

James Dalton, the founder of GTx, is the big man in the field of SARMs. He and his co-workers made andarine,
which is also known in chemical sports as S4 [structural formula below right].
They also made ostarine, which you might also know as GTx-024, MK-2866 or enobosarm [structural formula below left].
Just like andarin, ostarine has now emerged in the chemical sport.
German researchers found it in preparations that sold web shops open and bare.



ostarineandarinestructure.gif



enobosarm.gif


In the 3 mg dose, ostarine increased the fat-free mass by 1.4 kg. That effect was statistically significant.Ostarine also
increased the
power that the test subjects developed on a stair climber.

The test subjects did not train.
The fat mass decreased slightly by 300 grams in the 3 mg group.
That effect was also statistically significant.

Doctors hope that SARMs do not suppress the body's own testosterone production in men.
The table below - which only concerns the men in the study - below shows that ostarine does a bit of that. A little bit.

lqpnGRQ.png


Ostarine lowers the 'good cholesterol' HDL level. That effect is also not very strong, but in a discussion of Dalton's study, two German specialists are still a bit worried about it.
[J Cachexia Sarcopenia Muscle. 2011 Sep; 2 (3): 121-123.] "
The HDL decrease is still of some concern as this is a proof that there are still unwanted side and
not tissue-selective effects or this novel non-steroidal selective androgen modulator ", they write.

Ostarine, just like 17-alpha-methyl-anabolics, probably does burden the liver to a greater or lesser extent. In Dalton's research, the concentration of the enzyme alanine aminotransferase [ALT]
increased in twenty percent of the subjects.
A high ALT level can indicate liver damage.

After all, Dalton also looked at whether women got more body hair from ostarine. That was not the case.
" GTx-024 provides beneficial anabolic effects on total lean body mass and physical function without the adverse consequences
often seen with testosterone and other anabolic steroids,

" the study concludes. " These data support the development of GTx-024 for treatment and prevention
of muscle wasting in patients with chronic diseases
."

Source:
J Cachexia Sarcopenia Muscle. 2011 Sep; 2 (3): 153-161.

 
As expected. Some suppression noticed as well as small effects on HDL. Pretty on par with my experiences with Osta. The suppression is hardly noticeable if at all and the lipids return to normal shortly after stopping. I always loved the Osta/S4 combo. Can't beat it.
 
Back
Top